NCT01164176已完成2 期
An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 7
- 主要终点
- Response rate
研究概览
简要总结
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well everolimus works in treating patients with locally advanced or metastatic thyroid cancer.
详细描述
OBJECTIVES:
Primary
- To evaluate response rate in patients with locally advanced or metastatic, unresectable or refractory thyroid cancer treated with everolimus.
Secondary
- To evaluate overall survival of these patients treated with everolimus.
- To evaluate progression-free survival of these patients.
- To evaluate toxicity of this therapy in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
RAD001 group
Experimental
干预措施: everolimus (Drug)
RAD001 group
Experimental
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Response rate
时间窗: every 3 month
次要结局
- Overall survival(participants will be followed until death)
- Progression-free survival(participants will be followed until disease progression or death)
- Toxicity profile(participants will be followed until disease progression or death)
研究者
研究点 (7)
Loading locations...
相似试验
终止
2 期
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous TherapyColorectal CancerNCT00390364Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
Unknown
2 期
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid CancerHead and Neck CancerNCT01118065Leiden University Medical Center42
已完成
1 期
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaBrain and Central Nervous System TumorsNCT00553150Alliance for Clinical Trials in Oncology122
撤回
2 期
Everolimus in Treating Women With Breast Cancer That Can Be Removed by SurgeryBreast CancerNCT00855114Masonic Cancer Center, University of Minnesota
已完成
1 期
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT01062399Radiation Therapy Oncology Group279